22.27
5.20%
1.10
アフターアワーズ:
22.27
前日終値:
$21.17
開ける:
$21.29
24時間の取引高:
274.11K
Relative Volume:
0.72
時価総額:
$677.65M
収益:
$17.16M
当期純損益:
$-163.62M
株価収益率:
-4.2909
EPS:
-5.19
ネットキャッシュフロー:
$-121.61M
1週間 パフォーマンス:
+17.21%
1か月 パフォーマンス:
-36.64%
6か月 パフォーマンス:
-11.06%
1年 パフォーマンス:
+56.83%
Anaptysbio Inc Stock (ANAB) Company Profile
名前
Anaptysbio Inc
セクター
電話
858-362-6295
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
ANAB | 22.27 | 677.65M | 17.16M | -163.62M | -121.61M | -5.19 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-05-22 | アップグレード | JP Morgan | Underweight → Neutral |
2023-05-18 | 開始されました | TD Cowen | Outperform |
2023-01-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2022-11-01 | アップグレード | Guggenheim | Neutral → Buy |
2022-09-19 | 再開されました | H.C. Wainwright | Buy |
2022-09-13 | ダウングレード | Truist | Buy → Hold |
2022-09-01 | 開始されました | Raymond James | Outperform |
2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
2021-06-22 | 開始されました | H.C. Wainwright | Buy |
2021-05-21 | 開始されました | UBS | Neutral |
2021-03-16 | アップグレード | Truist | Hold → Buy |
2021-03-09 | ダウングレード | Wedbush | Outperform → Neutral |
2021-03-08 | ダウングレード | JP Morgan | Overweight → Underweight |
2021-02-11 | アップグレード | JP Morgan | Underweight → Overweight |
2020-10-27 | アップグレード | Wedbush | Neutral → Outperform |
2020-10-14 | アップグレード | Guggenheim | Neutral → Buy |
2019-11-08 | ダウングレード | JP Morgan | Overweight → Underweight |
2019-11-08 | ダウングレード | Jefferies | Buy → Hold |
2019-11-08 | ダウングレード | SunTrust | Buy → Hold |
2019-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
2019-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
2019-06-21 | ダウングレード | Stifel | Buy → Hold |
2018-12-20 | 開始されました | H.C. Wainwright | Buy |
2018-11-21 | 開始されました | JP Morgan | Overweight |
2018-07-19 | 開始されました | Credit Suisse | Outperform |
2018-04-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2018-03-27 | 繰り返されました | Stifel | Buy |
2018-03-06 | 繰り返されました | Stifel | Buy |
2018-02-15 | 繰り返されました | SunTrust | Buy |
2018-01-23 | 繰り返されました | Credit Suisse | Outperform |
2017-11-15 | 開始されました | SunTrust | Buy |
2017-11-09 | 開始されました | Jefferies | Buy |
2017-10-11 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Anaptysbio Inc (ANAB) 最新ニュース
Jennison Associates LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Victory Capital Management Inc. Increases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching - Seeking Alpha
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) - MSN
Truist maintains hold on AnaptysBio with $30 target By Investing.com - Investing.com UK
AnaptysBio’s (ANAB) “Outperform” Rating Reiterated at Wedbush - Defense World
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $54.64 - MarketBeat
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Yahoo Finance
JPMorgan Chase & Co. Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
(ANAB) Proactive Strategies - Stock Traders Daily
Leerink Partnrs Lifts Earnings Estimates for AnaptysBio - Defense World
What is Wedbush’s Forecast for AnaptysBio FY2024 Earnings? - Defense World
FY2024 EPS Estimates for AnaptysBio Lifted by HC Wainwright - Defense World
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
What is Wedbush's Forecast for AnaptysBio FY2024 Earnings? - MarketBeat
HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Earns “Outperform” Rating from Wedbush - Defense World
Lilly bid wilts as others forge on with PD-1 in RA - BioWorld Online
AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet - Simply Wall St
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - Defense World
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates - MSN
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Earnings Beat - MarketBeat
AnaptysBio shares hold Outperform rating; Leerink notes strong cash position and clinical progress - Investing.com UK
AnaptysBio stock target cut on increased expenses By Investing.com - Investing.com Canada
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright - StreetInsider.com
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners - StreetInsider.com
AnaptysBio Inc (ANAB) Q3 2024 Earnings: Revenue Soars to $30M, E - GuruFocus.com
AnaptysBio Reports Q3 2024 Financial Results and Updates - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c - StreetInsider.com
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Anaptys Announces Participation in November and December Investor Conferences - The Manila Times
AnaptysBio's Q3 Revenue Surges to $30M, Cash Position Hits $458M Ahead of Key Trial Data | ANAB Stock News - StockTitan
AnaptysBio CEO to Present at 4 Major Healthcare Conferences Through Year-End | ANAB Stock News - StockTitan
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4%Here's What Happened - MarketBeat
Things To Consider Before Buying AnaptysBio Inc (NASDAQ: ANAB) - Stocks Register
AnaptysBio: Too Risky, Especially After LLY Drops Its Related Programs - Seeking Alpha
AnaptysBio (ANAB) Shares Plunge as Eli Lilly Ends Arthritis Drug Research - GuruFocus.com
AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright - MarketBeat
(ANAB) Trading Advice - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Gap DownHere's What Happened - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $33.00 - MarketBeat
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
AnaptysBio stock falls as Lilly updates pipeline (ANAB:NASDAQ) - Seeking Alpha
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - TradingView
Assenagon Asset Management S.A. Grows Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 6.9%Here's Why - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from Analysts - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 - Defense World
nVerses Capital LLC Buys 1,400 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Anaptysbio Inc (ANAB) 財務データ
収益
当期純利益
現金流量
EPS
Anaptysbio Inc (ANAB) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Lizzul Paul F. | Chief Medical Officer |
Sep 23 '24 |
Sale |
38.67 |
1,500 |
58,005 |
15,398 |
大文字化:
|
ボリューム (24 時間):